An open label study to investigate the safety and tolerability of GK Activator (2) in patients with type 2 diabetes mellitus not adequately controlled with glimepiride as a standard prescribed therapy.

Trial Profile

An open label study to investigate the safety and tolerability of GK Activator (2) in patients with type 2 diabetes mellitus not adequately controlled with glimepiride as a standard prescribed therapy.

Completed
Phase of Trial: Phase I

Latest Information Update: 23 Feb 2010

At a glance

  • Drugs Glimepiride; Piragliatin
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions
  • Sponsors Roche
  • Most Recent Events

    • 23 Feb 2010 Actual initiation date (Aug 2006) added as reported by Roche.
    • 08 Jan 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top